Perspective

Chromosome Instability, Aging and Brain Diseases

Ivan Y. Iourov 1,2,3,*, Yuri B. Yurov 1,2, Svetlana G. Vorsanova 1,2 and Sergei I. Kutsev 4

Abstract: Chromosome instability (CIN) has been repeatedly associated with aging and progeroid phenotypes. Moreover, brain-specific CIN seems to be an important element of pathogenic cascades leading to neurodegeneration in late adulthood. Alternatively, CIN and aneuploidy (chromosomal loss/gain) syndromes exhibit accelerated aging phenotypes. Molecularly, cellular senescence, which seems to be mediated by CIN and aneuploidy, is likely to contribute to brain aging in health and disease. However, there is no consensus about the occurrence of CIN in the aging brain. As a result, the role of CIN/somatic aneuploidy in normal and pathological brain aging is a matter of debate. Still, taking into account the effects of CIN on cellular homeostasis, the possibility of involvement in brain aging is highly likely. More importantly, the CIN contribution to neuronal cell death may be responsible for neurodegeneration and the aging-related deterioration of the brain. The loss of CIN-affected neurons probably underlies the contradiction between reports addressing ontogenetic changes of karyotypes within the aged brain. In future studies, the combination of single-cell visualization and whole-genome techniques with systems biology methods would certainly define the intrinsic role of CIN in the aging of the normal and diseased brain.

Keywords: aging; aneuploidy; brain diseases; chromosome; chromosome instability; genome instability; neurodegeneration

1. Introduction

Sixty years ago, intercellular changes in chromosome numbers were demonstrated to be a possible cellular mechanism of human aging [1]. Later on, aging was systematically associated with the accumulation of aneuploid cells (i.e., cells exhibiting the loss/gain of whole chromosomes) and, occasionally, with chromosome instability (CIN) [2–4]. Furthermore, the rates of the latter were found to increase throughout ontogeny, as documented by studying the variability of cancer genomes [5,6]. Currently, somatic chromosomal mosaicism (mosaic aneuploidy) and CIN are suggested to contribute to aging processes in health and disease [7]. Still, the causes and consequences of CIN in aging postmitotic tissues remain poorly understood.

Genome instability (including instability at the chromosomal/subchromosomal level) seems to be involved in the normal and pathogenic aging of the human brain [8,9]. CIN-associated diseases (i.e., CIN syndromes) exhibit progeroid phenotypes and/or cellular phenotypes hallmarking aging processes [10,11]. Significantly, CIN may represent a mechanism for neurodegeneration in diseases featured by accelerated aging [12]. Similarly, the brain of individuals suffering from Alzheimer’s disease (a late-onset neurodegenerative disease suggested to be linked somehow to pathological brain aging) is char-
characterized by high rates of CIN [13], which mainly manifests as aneuploidy [14–16]. In total, somatic mutagenesis leading to CIN and chromosomal mosaicism may be considered an element of molecular and cellular pathways to normal and pathogenic aging mediating a variety of diseases [17]. If CIN is confined to the brain, one may expect a progressive neuropathological process resulting in a devastating neuropsychiatric illness. Among the latter, aging-related neurodegenerative diseases are the most common ones [7,15,18]. Accordingly, understanding the interplay between CIN and brain aging appears to be a key for unraveling the mechanisms of neurodegeneration and explaining brain deterioration in late life.

Here, we address ontogenetic aspects of CIN in light of brain aging with a special focus on neurodegenerative diseases. Heterogeneous data about CIN in the aging brain is considered in the context of forthcoming research dedicated to cytogenomic solutions to problems surrounding genome behavior during brain aging, pathways to age-related CIN, possible antiaging therapy, and the detection of the intrinsic rates of CIN in the healthy and diseased brain.

2. CIN in the Human Brain: An Ontogenetic View

CIN and mosaic aneuploidy are considered to play a role in brain development and functioning [7,19]. These types of genomic variations are more likely to possess a special meaning for the brain due to the organizational specificity of the central nervous system. Briefly, even a small proportion of genetically abnormal (neuronal) cells might affect brain functioning because of a multitude of intercellular connections (synapses) [14,20]. Taking into account the post-mitotic nature of the mammalian brain, the origins of brain-specific CIN are more likely to be developmental. The developing human brain (8–11 weeks) is shown to be significantly affected by CIN almost exclusively manifesting as aneuploidy. The proportions of abnormal cells may achieve 30–35% [21,22]. At the subchromosomal level, copy number variations (CNVs) below 1 Mb in size are found to underlie the genomic diversification of cells in the developing mammalian brain [23,24]. However, since large-scale intercellular genomic variations (e.g., aneuploidy) are exclusive at later developmental stages [24], an extensive decrease of CIN-affected cells is likely to exist. As reportedly noted, brain-specific developmental CIN significantly decreases to become less abundant in the postnatal brain through a sophisticated mechanism of regulating neural populations (e.g., aneuploidyization followed by mitotic catastrophe) [3,17,19,25]. Postnatally, the result of these orchestrated changes could be traces of the presence of abnormal neural cells during prenatal development. Alternatively, a variety of phenomena (DNA replication stress, cellular senescence [26,27]) are able to favor the conservation of CIN rates or even promote CIN progression after birth throughout adulthood. When transformed into an appreciable population, cells affected by CIN/somatic mosaicism are able to become a source for morbidity and aging [28–30]. Moreover, alterations to a number of molecular/cellular pathways (DNA damage response; RNA somatic gene recombination; mTOR, PI3K-Akt, p53, PTEN, MAPK) predispose to CIN/mosaic aneuploidy in the diseased and aged brain [31–33]. To highlight the contribution of CIN to normal and pathological brain aging, it seems important to address aging-associated diseases characterized by brain malfunction (e.g., neurodegeneration) and brain-specific CIN.

3. CIN in the Diseased Brain: An Aging Perspective

During the last two decades, an appreciable amount of data on chromosomal variations (aneuploidy) and CIN directly affecting the brain was provided. Currently, it is suggested that several neurodevelopmental, psychiatric and neurodegenerative disorders may be associated with CIN and somatic chromosomal mosaicism confined to the brain or even to specific brain areas [12,14,16,18–20,33,34]. Brain tissue-specific chromosomal mosaicism and CIN are detectable in a significant proportion of cases of common brain diseases, including schizophrenia, autism/intellectual disability and Alzheimer’s disease.
[7,18,30,33]. However, CIN is a significantly more prominent biomarker of neurodegeneration (neurodegenerative diseases) when comparing intercellular chromosomal or (cyto)genomic variations between different types of brain disorders with a special emphasis on brain aging [12–16,34,35].

Neurodegenerative diseases (Alzheimer’s disease and common non-Alzheimer’s disease dementias) are systematically associated with a wide spectrum of genomic variations. Among others, these genomic changes may affect molecular (cellular) pathways of genome stability maintenance or protection against CIN (e.g., cell cycle regulation) [36,37]. The ability for neurons to enter erroneously into the cell cycle seems to underlie the formation of aneuploidy and other types of CIN in the diseased (Alzheimer’s disease) brain [9,34,35,38,39]. Actually, CIN/aneuploidy confined to affected brain areas has been determined as an important element of the pathogenic cascade in Alzheimer’s disease [40,41]. In addition, the Alzheimer’s disease brain has been shown to exhibit a variety of CIN types. Moreover, a number of parallels between Alzheimer’s disease and cancer directly related to cellular phenotypes and pathological processes leading to CIN/aneuploidy appear to exist [42]. More crucially, genes associated with Alzheimer’s disease (including genes mutated in rare familial cases) may induce chromosome missegregation and aneuploidy, leading to CIN in the diseased brain [40,43,44]. Brain-specific Alzheimer’s disease-associated aneuploidy/CIN more commonly involves chromosome 21 (note: APP (Amyloid Beta Precursor Protein) gene is located on chromosome 21) [14,16,44]. These findings correlate with long-standing observations concerning neurological and molecular parallels between Alzheimer’s disease and Down syndrome (trisomy of chromosome 21 or the presence of an extra chromosome 21 in the overwhelming majority of cells) [45]. Furthermore, X chromosome aneuploidy or X chromosome loss/monosomy [46] (i.e., CIN specifically affecting chromosome X [35]) has been found to hallmark the Alzheimer’s disease brain. It is of note that X chromosome loss is the most documented cytogenetic (chromosomal) biomarker of human aging [2,4]. CNVs, resulting from somatic recombination and selectively affecting the APP gene, have also been found to produce genomic or subchromosomal instability in the Alzheimer’s disease brain [47]. This type of genomic mosaicism is probably the result of the somatic gene recombination of mRNA/ncRNA [32]. Uncorrected DNA damage, which is able to initiate CIN, is also a biomarker of Alzheimer’s disease [48]. At the proteomic level, the abnormal functioning of cell cycle proteins is suggested to produce aneuploidy and other CIN types in post-mitotic neurons of the Alzheimer’s disease brain [49]. Finally, DNA replication stress appears to underlie CIN in the Alzheimer’s disease brain, allowing a theoretical link between two major hypotheses of the disease: the amyloid hypothesis and cell cycle hypothesis [50]. These data on genome/chromosome behavior in the Alzheimer’s disease brain have been commonly correlated with disease phenotype and peculiarities (e.g., sex differences) [44,45,51]. In summary, despite the debates concerning the contribution of brain aging to the pathophysiology of Alzheimer’s disease, one has to admit the involvement of CIN, which mediates aging in mitotic tissues and initiates from aging-related alterations to cellular homeostasis, in the pathogenic cascade.

It is noteworthy that Alzheimer’s disease is not the unique neurodegenerative disorder associated with aneuploidy and/or CIN. A CIN syndrome characterized by accelerated aging and neurodegeneration (ataxia-telangiectasia) exhibits cerebellar-specific CIN (chromosome breaks and rearrangements), which mediates neurodegeneration [12] and brain-specific aneuploidy [14]. Furthermore, the ataxia-telangiectasia brain picturesquely demonstrates region-specific effects of CIN. Thus, chromosome 14-specific instability (interphase chromosome breaks and additional rearranged chromosomes 14) confined to the cerebellum mediates neurodegeneration [12]. When analyzing regional genomic DNA content variation in different cortical areas of the Alzheimer’s disease brain, traces of a similar effect have been observed [34].
Lewy body diseases have been associated with aneuploidy in the diseased brain [52]. More strikingly, frontotemporal lobar degeneration caused by MAPT (microtubule-associated protein tau) mutations has been found to exhibit mitotic defects that lead to neuronal aneuploidy and apoptosis in the diseased brain [53]. Additionally, MAPT mutations cause CIN and introduce CNVs widely in the genome [54]. Interestingly, CNVs appreciably contribute to the most common aging-related neurodegenerative disorders [55]. Unfortunately, there are few studies dedicated to analyzing brain-specific CIN in other neurodegenerative conditions than Alzheimer’s disease. Still, genetic and (cyto)genomic analyses of the neurodegenerating brain have connected mutations in genes involved in safeguarding genome stability, CIN and molecular pathways in neurodegenerative diseases [33]. Similarly to Alzheimer’s disease [40,44], mitotic dysfunction and cell cycle errors are common features of neurodegenerative diseases, as a whole [56]. Recently, a theoretical model has allowed the determination of the difference between cancerous and neurodegenerative CIN. Neuronal cell death seems to be a key element of the pathogenic cascade initiating the progressive loss of cells affected by CIN [57]. Therefore, one can conclude that the culminating of brain-specific CIN accumulation is likely to be a starting point for the progressive clearance of neurons leading to neurodegeneration.

In addition to genome stability maintenance, cell cycle regulation and neuronal cell death, it is worth mentioning cellular senescence in the light of brain aging and neurodegenerative diseases. Cell senescence represents a homeostatic process characterized by sustained cell cycle arrest and a distinct cellular phenotype. It is able to make a contribution to a decrease in the regenerative potential and to alterations of tissue functioning. Cellular senescence is currently suggested to be involved in the pathophysiology of neurodegenerative diseases and brain aging [58–60]. Despite the lack of consensus on the role of cell senescence in Alzheimer’s disease pathology, it is accepted that the cellular senescence pathway is tightly connected to the neurodegenerative processes during brain aging [60]. The presence of senescent cells in a tissue hallmarks aging-related processes in health and disease [61]. Admittedly, interplay between CIN, pathways to CIN and cellular senescence would be a missing link in the pathophysiology of normal and abnormal brain aging.

4. CIN in the Aged Brain: The Shape of Things to Come

Focusing on cellular senescence has revealed the tight connection to cell cycle regulation, neuronal cell death and genome stability maintenance in the aged brain [61,62]. Furthermore, aging-related mechanisms for neurodegeneration have the potential to lead both to CIN and cellular senescence [63,64]. As systematically shown, cell senescence is linked to genome instability/CIN and neuronal cell death [31,65,66]. This link has been additionally demonstrated by a study that shows the inhibition of aging-associated CIN delaying cellular senescence [67]. Taking into account the dynamic nature of CIN and somatic mosaicism rates both in mitotic and post-mitotic cellular populations [68], one may suggest that cellular senescence arises from CIN in brain aging. This idea is further supported by a line of evidences for CIN manifesting as aneuploidy progressing in the aged brain [69–71]. It is of note that the traces of mitotic dysfunction hallmarking aging [72] have been found in the aged and diseased brain [9,25,34]. Moreover, the genetic-environmental interactions in the brain of individuals with aging-related diseases and CIN involve molecular pathways of programmed cell death and genome stability maintenance [73]. Thus, CIN affecting the aged brain explains a number of aging-related phenomena/processes (cellular senescence, mitotic machinery exhaustion, (neuronal) cell loss, proinflammatory response), which define tissular and cellular phenotypes specific for aging [3,29,59,74]. Chromosome-specific instability (e.g., chromosome 14-specific instability—ataxia-telangiectasia; chromosome 21-specific instability—Alzheimer’s disease) appears to represent another possible mechanism for the age-dependent malfunction of the brain. At this point, the involvement of X-chromosome-specific aneuploidy (X-chromosome-specific instability) may help to explain sex differences in the aging of the healthy
and diseased (Alzheimer’s disease) brain. More precisely, increased rates of X chromosome loss (specific for female karyotypes) in the Alzheimer’s disease brain [46] might specifically contribute to the disease course in females [51,75]. X-chromosome-specific aneuploidy may not be a unique type of CIN contributing to sex differences in the Alzheimer’s disease brain [35]. Finally, DNA replication stress and DNA double-strand breaks are able to result in somatic CNVs affecting smaller genomic regions comparing to aneuploidy (i.e., whole chromosomes gains/losses) [50,76]. Since CNVs are able to contribute to common aging-related neurodegenerative diseases [55], it is probable that CIN generated by CNVs, which has the potential to progress and affect cellular homeostasis (for more details, see [77]), can also contribute to normal and pathological brain aging. In turn, this CIN type, being poorly compatible with the cellular lifespan, may lead to neuronal cell death.

Onto(cyto)genetic views on the human brain allowed us to propose a kind of a model for neural genome behavior in connection to CIN and normal/pathological aging. On the one hand, brain-specific CIN producing senescence in neuronal cell populations may progress slowly throughout the adult life, whereas on the other hand CIN may become a trigger for progressive neuronal cell death in late ontogeny. While it certainly exists, a ‘point of no return’ for CIN-mediated neuronal cell death has not been comprehensively described. We believe that either critically adverse effects on cellular homeostasis produced by CIN or CIN-initiated programmed cell death (e.g., mitotic catastrophe) may be involved. In aging-related brain diseases, the process of losing CIN-affected cells is likely to be more dramatic (fast) and to begin earlier than in presumably unaffected individuals. The differences between pathological and normal brain aging may result from variable degrees of alterations to the aforementioned pathways. An additional source for the difference might be chromosome breakages or CNVs produced by CIN, which lead to improper functioning (activation/inactivation) of different spectra of genes in the affected neuronal cell population. However, such an effect has not as yet been empirically addressed. In total, CIN is likely to be involved in cell number regulation during early and late ontogeny or in neurodegeneration. Figure 1 demonstrates the essence of our assumption concerning the changes in the rates of brain-specific CIN by indicating the trendlines of brain-specific CIN rates through ontogeny and highlighting suggested periods of progressive neuronal cell death in health and disease.
Figure 1. Schematic depiction of changes in chromosome instability CIN rates in the context of brain aging and neurodegeneration indicating trends of brain-specific CIN rates through ontogeny and/or the course of life and suggested periods of progressive neuronal cell death in health and disease (natural and neurodegeneration, respectively): 1 or reddish trendline—CIN trend for early onset neurodegenerative diseases with accelerated aging phenotypes, e.g., ataxia-telangiectasia; 2 or blueish trendline—CIN trend for late onset neurodegenerative diseases; 3 or yellowish trendline—natural CIN trend.

The dynamic nature of CIN and somatic chromosomal mosaicism has been recently suggested as a target for the exogenous control of the rates. The control is an opportunity for the diminishment of CIN rates and, consequently, for tissue rejuvenation, increasing the lifespan and slowing down disease progression [68]. In the available literature, suggestions concerning the realization of this idea have been already proposed. It is more likely that genetic-environmental interactions may help to inhibit CIN or eliminate affected cells at early stages of aging and/or disease [71,73]. A candidate process for these interactions would be mitotic/cell cycle regulation, programmed cell death and cellular senescence [49,53,59,60,64]. For instance, the analysis of DNA damage response in neurons shows the possibility of switching between programmed cell death (apoptosis) and a pseudo-stationary cellular state (senescence-like state) [31]. Currently, following targets for therapeutic interventions in aging and neurodegeneration has been empirically defined: DNA double-strand breaks [76], aging-associated CIN (the inhibition by small-molecule enhancement of microtubule-depolymerizing kinesin-13 activity delays cellular senescence) [67], somatic gene recombination of mRNA/ncRNA [32], and the deterioration of nuclear morphology and architecture mediated by cell senescence [78]. As was recently noted, ‘the aging genome’ is to be protected for successful antiaging therapies [79]. It is more probable that the basis of these therapies is a pathway-based analysis providing an opportunity to define molecular interventions towards longevity in health and disease [80,81]. To perform such an analysis, a closer look at the whole set of genomic changes produced by CIN is required [82,83]. Additionally, determining the susceptibility/tolerance to brain-specific CIN using a whole-genome scan and systems biology techniques may be useful for preventing/inhibiting CIN progression and related processes [68,73,82]. Summarizing neurogenomic and molecular neurocytogenetic data leads one to conclude...
that CIN-related pathways are promising targets for antiaging therapy or brain rejuvenation and for therapeutic interventions in neurodegenerative diseases. Therefore, possible therapeutic strategies are likely to be based on molecular cytogenetic (cytogenomic), whole-genome and systems biology analyses focused on the interplay between the genetic and environmental causes of CIN in the brain.

To this end, we have to mention that data on aneuploidy that was found to be increased in the aged brain by visualization techniques [69–71] do not conform to data obtained by studies using single-cell whole-DNA-fraction analyses, which have shown a lack of aneuploid cells in the aged human neocortex [84]. To solve this problem, we can propose the use of a previously described workflow proposed for the single-cell analysis of cellular genomes in the brain. The workflow combines molecular cytogenetic (visualization), whole-genome (single-cell and multiple-cell analysis of DNA fractions) and systems biology (bioinformatics) techniques (for more details, see [85]). Alternatively, one can suppose that CIN-affected neuron loss via neuronal cell death explains the contradiction between reports addressing ontogenetic changes in karyotypes within the aged brain. In other words, a number of (cyto)genomic studies address the aged brain at the ontogenetic stages when CIN-affected neurons have been already lost. In the future, single-cell analysis using the workflow mentioned below may help to uncover the basis of the discrepancies between studies on chromosome complements in the aged brain.

5. Concluding Remarks

In 1990, about 300 hypotheses for aging were described in the available literature [86]. Since then, the list has been extended by those dealing with mitotic machinery exhaustion, genome instability/CIN in post-mitotic tissues, programmed death of post-mitotic cells, DNA replication stress, DNA damage response, DNA repair, DNA double-strand breaks, etc. [16,25,48,50,57,65,66,75]. Nonetheless, a generalized theory encompassing the majority of original ideas expressed in these hypotheses does not exist. To simplify the modeling of aging, nine tentative hallmarks were introduced. These are: genomic instability (1), telomere attrition (2), epigenetic alterations (3), loss of proteostasis (4), deregulated nutrient sensing (5), mitochondrial dysfunction (6), cellular senescence (7), stem cell exhaustion (8) and altered intercellular communication (9) [66]. As one may see, at least four of these hallmarks (1–3 and 7) are related to CIN. More importantly, genomic instability (genomic instability and CIN interfere with each other) and cellular senescence are involved in the pathogenesis of aging-related (neurodegenerative) brain diseases. Furthermore, it appears that the aging-related deterioration of the brain is likely to be mediated by a cascade that involves CIN, cell senescence and neuronal cell death. We suppose that brain-specific CIN rates are able to increase slowly throughout adulthood. However, during later ontogenetic periods, CIN-affected neurons are likely to be cleared by neuronal cell death. As a result, the number of neurons in the aged brain may be significantly diminished. In neurodegenerative diseases, these processes are more dramatic and are, thereby, more apparent than in natural brain aging. Thus, CIN and cell senescence pathways might be a target for antiaging therapy (brain rejuvenation) and therapeutic interventions in debilitating neurodegenerative disorders. Certainly, a model based on the sophisticated interplay between cell cycle regulation, DNA repairation, CIN and cellular senescence should not be considered as the ultimate one. We suggest that a synthesis of the rationales obtained by aging studies from different areas of biomedicine is the most promising way to understand human aging.

Future research dedicated to the genetic and (cyto)genomic aspects of brain aging has to combine visualization, whole-genome (single-cell/multiple-cell analysis of DNA fractions) and systems biology (bioinformatics) techniques for the determination of intrinsic CIN/aneuploidy rates and CIN-associated cellular phenotypes (e.g., cellular senescence). Once acquired, this knowledge can be used to develop effective strategies for brain rejuvenation and neurodegeneration treatment.
Author Contributions: I.Y.I. wrote the manuscript and made a significant theoretical contribution. Y.B.Y. and S.G.V. made a significant theoretical contribution. S.I.K. made a theoretical contribution. All authors have read and agreed to the published version of the manuscript.

Funding: I.Y.I. and S.G.V. are partially supported by RFBR and CITMA according to the research project no. 18–515-34005; prof. IY Iourov’s lab is supported by the Government Assignment of the Russian Ministry of Science and Higher Education, Assignment no. AAAA–A19–119040490101-6; prof. SG Vorsanova’s lab is supported by the Government Assignment of the Russian Ministry of Health, Assignment no. 121031000238-1.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We thank Vasilisa Iurova for Figure 1.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Jacobs, P.A.; Court Brown, W.M.; Doll, R. Distribution of human chromosome counts in relation to age. Nature 1961, 191, 1178–1180.
2. Russell, L.M.; Strike, P.; Browne, C.E.; Jacobs, P.A. X chromosome loss and ageing. Cytogenet. Genome Res. 2007, 116, 181–185.
3. Yurov, Y.B.; Vorsanova, S.G.; Iourov, I.Y. Ontogenetic variation of the human genome. Curr. Genom. 2010, 11, 420–425.
4. Dai, X.; Guo, X. Decoding and rejuvenating human ageing genomes: Lessons from mosaic chromosomal alterations. Ageing Res. Rev. 2021, 68, 101342.
5. Simonetti, G.; Bruno, S.; Padella, A.; Tenti, E.; Martinelli, G. Aneuploidy: Cancer strength or vulnerability? Int. J. Cancer 2019, 144, 8–25.
6. Heng, J.; Heng, H.H. Genome chaos: Creating new genomic information essential for cancer macroevolution. Semin. Cancer Biol. 2020, doi:10.1016/j.semcancer.2020.11.003.
7. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B.; Kutsev, S.I. Ontogenetic and pathogenetic views on somatic chromosomal mosaicism. Genes 2019, 10, 379.
8. Kennedy, S.R.; Loeb, L.A.; Herr, A.J. Somatic mutations in aging, cancer and neurodegeneration. Mech. Ageing Dev. 2012, 133, 118–126.
9. Chow, H.M.; Herrup, K. Genomic integrity and the ageing brain. Nat. Rev. Neurosci. 2015, 16, 672–684.
10. Vijg, J.; Dong, X.; Milholland, B.; Zhang, L. Genome instability: A conserved mechanism of ageing? Essays Biochem. 2017, 61, 305–315.
11. Helbling-Leclerc, A.; Garcin, C.; Rosselli, F. Beyond DNA repair and chromosome instability—Fanconi anaemia as a cellular senescence-attributed syndrome. Cell Death Differ. 2021, 28, 1159–1173.
12. Iourov, I.Y.; Vorsanova, S.G.; Liehr, T.; Kolotii, A.D.; Yurov, Y.B. Increased chromosome instability dramatically disrupts neural genome integrity and mediates cerebellar degeneration in the ataxia-telangiectasia brain. Hum. Mol. Genet. 2009, 18, 2656–2669.
13. Hou, Y.; Song, H.; Croteau, D.L.; Akbari, M.; Bohr, V.A. Genome instability in Alzheimer disease. Mech. Ageing Dev. 2017, 161, 83–94.
14. Iourov, I.Y.; Vorsanova, S.G.; Liehr, T.; Yurov, Y.B. Aneuploidy in the normal, Alzheimer’s disease and ataxia-telangiectasia brain: Differential expression and pathological meaning. Neurobiol. Dis. 2009, 34, 212–220.
15. Shepherd, C.E.; Yang, Y.; Halliday, G.M. Region- and cell-specific aneuploidy in brain aging and neurodegeneration. Neuroscience 2018, 374, 326–334.
16. Potter, H.; Chial, H.J.; Caneus, J.; Elos, M.; Elder, N.; Borysov, S.; Granic, A. Chromosome instability and mosaic aneuploidy in neurodegenerative and neurodevelopmental disorders. Front. Genet. 2019, 10, 1092.
17. Zhang, L.; Vijg, J. Somatic mutagenesis in mammals and its implications for human disease and aging. Annu. Rev. Genet. 2018, 52, 397–419.
18. Jourdon, A.; Fasching, L.; Scuderi, S.; Abyzov, A.; Vaccarino, F.M. The role of somatic mosaicism in brain disease. Curr. Opin. Genet. Dev. 2020, 65, 84–90.
19. Rohrback, S.; Siddoway, B.; Liu, C.S.; Chun, J. Genomic mosaicism in the developing and adult brain. Dev. Neurobiol. 2018, 78, 1026–1048.
20. Graham, E.J.; Vermeulen, M.; Vardarajan, B.; Bennett, D.; De Jager, P.; Pease, R.V., II; Young-Pearse, T.L.; Mostafavi, S. Somatic mosaicism of sex chromosomes in the blood and brain. Brain Res. 2019, 1721, 146345.
21. Yurov, Y.B.; Iourov, I.Y.; Monakhov, V.V.; Soloviev, I.V.; Vostrikov, V.M.; Vorsanova, S.G. The variation of aneuploidy frequency in the developing and adult human brain revealed by an interphase FISH study. J. Histochem. Cytochem. 2005, 53, 385–390.
22. Yurov, Y.B.; Iourov, I.Y.; Vorsanova, S.G.; Liehr, T.; Kolotii, A.D.; Kutsev, S.I.; Pellestor, F.; Beresheva, A.K.; Demidova, I.A.; Kravets, V.S.; et al. Aneuploidy and confined chromosomal mosaicism in the developing human brain. *PLoS ONE* **2007**, *2*, e558.

23. Rohrback, S.; April, C.; Kaper, F.; Rivera, R.R.; Liu, C.S.; Siddoway, B.; Chun, J. Submegabase copy number variations arise during cerebral cortical neurogenesis as revealed by single-cell whole-genome sequencing. *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 10804–10809.

24. Sekar, S.; Tomasini, L.; Proukakis, C.; Bae, T.; Manlove, L.; Jang, Y.; Scuderi, S.; Zhou, B.; Kalyva, M.; Amiri, A.; et al. Complex mosaic structural variations in human fetal brains. *Genome Res.* **2020**, *30*, 1695–1704.

25. Yurov, Y.B.; Vorsanova, S.G.; Iourov, I.Y. GIN’n’CIN hypothesis of brain aging: Deciphering the role of somatic genetic instabilities and neural aneuploidy during ontogeny. * Mol. Cytogenet.* **2009**, *2*, 23.

26. Wilhelm, T.; Said, M.; Naim, V. DNA replication stress and chromosomal instability: Dangerous liaisons. *Genes* **2020**, *11*, 642.

27. Sah, E.; Krishnamurthy, S.; Ahmadouch, M.Y.; Gillispie, G.J.; Milligan, C.; Orr, M.E. The cellular senescence stress response in post-mitotic brain cells: Cell survival at the expense of tissue degeneration. *Life Sci.* **2021**, *119*, 229.

28. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Chromosomal mosaicism goes global. *Mol. Cytogenet.* **2008**, *1*, 26.

29. Vijg, J. Somatic mutations, genome mosaicism, cancer and aging. *Curr. Opin. Genet. Dev.* **2014**, *26*, 141–149.

30. Thorpe, J.; Osei-Owusu, I.A.; Avigdor, B.E.; Tupler, R.; Pevsner, J. Mosaicism in human health and disease. *Annu. Rev. Genet.* **2020**, *54*, 487–571.

31. Fielder, E.; von Zglinicki, T.; Jurk, D. The DNA damage response in neurons: Die by apoptosis or survive in a senescence-like state? *J. Alzheimers Dis.* **2017**, *60*, S107–S131.

32. Ueberham, U.; Arendt, T. Genomic indexing by somatic gene recombination of mRNA ncRNA—Does it play a role in genomic mosaic mosaicism, memory formation, and Alzheimer’s disease? *Front. Genet.* **2020**, *11*, 370.

33. Iourov, I.Y.; Vorsanova, S.G.; Kurinnaia, O.S.; Zelenova, M.A.; Vasin, K.S.; Yurov, Y.B. Causes and consequences of genome instability in psychiatric and neurodegenerative diseases. *Mol. Biol.* **2021**, *55*, 37–46.

34. Arendt, T.; Brückner, M.K.; Löschle, A. Regional mosaic genomic heterogeneity in the elderly and in Alzheimer’s disease as a correlate of neuronal vulnerability. *Acta Neuropathol.* **2015**, *130*, 501–510.

35. Bajic, V.P.; Essack, M.; Zivkovic, L.; Stewart, A.; Zafrickovic, S.; Bajic, V.B.; Gojohori, T.; Isenovic, E.; Spremo-Potparevic, B. The X Files: “The mystery of X chromosome mosaicism in Alzheimer’s disease”. *Front. Genet.* **2020**, *10*, 1368.

36. Guerreiro, R.; Gibbs, E.; Tábuaus-Pereira, M.; Kun-Rodrigues, C.; Santo, G.C.; Bras, J. Genetic architecture of common non-Alzheimer’s disease dementias. *Neurobiol. Dis.* **2020**, *142*, 104946.

37. Neuner, S.M.; Tcw, J.; Goate, A.M. Genetic architecture of Alzheimer’s disease. *Neurobiol. Dis.* **2020**, *143*, 104976.

38. Malik, B.; Currais, A.; Andres, A.; Towlson, C.; Pitsi, D.; Nunes, A.; Nilbock, M.; Cooper, J.; Hortobágyi, T.; Soriano, S. Loss of neuronal cell cycle control as a mechanism of neurodegeneration in the presenilin-1 Alzheimer’s disease brain. *Cell Cycle* **2006**, *7*, 637–646.

39. Currais, A.; Hortobágyi, T.; Soriano, S. The neuronal cell cycle as a mechanism of pathogenesis in Alzheimer’s disease. *Aging* **2009**, *1*, 363–371.

40. Granic, D.; Padmanabhan, J.; Norden, M.; Potter, H. Alzheimer Abeta peptide induces chromosome mis-segregation and aneuploidy, including trisomy 21: Requirement for tau and APP. *Mol. Biol. Cell* **2010**, *21*, 511–520.

41. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Genomic landscape of the Alzheimer’s disease brain: Chromosome instability—Aneuploidy, but not tetraploidy—Mediates neurodegeneration. *Neurodegener. Dis.* **2011**, *8*, 35–37.

42. Nudelman, K.N.H.; McDonald, B.C.; Lahiri, D.K.; Saykin, A.J. Biological hallmarks of cancer in Alzheimer’s disease. *Mol. Neurobiol.* **2019**, *56*, 7173–7187.

43. Boeras, D.I.; Granic, A.; Padmanabhan, J.; Crespo, N.C.; Rojiani, A.M.; Potter, H. Alzheimer’s presenilin 1 causes chromosome missegregation and aneuploidy. *Neurobiol. Aging* **2008**, *29*, 319–328.

44. Bajic, V.; Spremo-Potparevic, B.; Zivkovic, L.; Isenovic, E.R.; Arendt, T. Cohesion and the aneuploid phenotype in Alzheimer’s disease: A tale of genome instability. *Neurosci. Biobehav. Rev.* **2015**, *55*, 365–374.

45. Snyder, H.M.; Bain, L.J.; Brickman, A.M.; Carrillo, M.C.; Ebensenn, A.J.; Espinosa, J.M.; Fernandez, F.; Fortea, J.; Hartley, S.L.; Head, E.; et al. Further understanding the connection between Alzheimer’s disease and Down syndrome. *Alzheimers Dement.* **2020**, *16*, 1065–1077.

46. Yurov, Y.B.; Vorsanova, S.G.; Liehr, T.; Kolotii, A.D.; Iourov, I.Y. X chromosome aneuploidy in the Alzheimer’s disease brain. *Mol. Cytogenet.* **2014**, *7*, 20.

47. Lee, M.H.; Siddoway, B.; Kaeser, G.E.; Segota, I.; Rivera, R.; Romanow, W.J.; Liu, C.S.; Park, C.; Kennedy, G.; Long, T.; et al. Somatic APP gene recombination in Alzheimer’s disease and normal neurons. *Nature* **2018**, *563*, 639–645.

48. Lin, X.; Kapoor, A.; Gu, Y.; Chow, M.J.; Peng, J.; Zhao, K.; Tang, D. Contributions of DNA damage to Alzheimer’s Disease. *Int. J. Mol. Sci.* **2020**, *21*, 1666.

49. van Leeuwen, L.A.; Hoozemans, J.J. Physiological and pathophysiological functions of cell cycle proteins in post-mitotic neurons: Implications for Alzheimer’s disease. *Acta Neuropathol.* **2015**, *129*, 511–525.

50. Yurov, Y.B.; Vorsanova, S.G.; Iourov, I.Y. The DNA replication stress hypothesis of Alzheimer’s disease. *Sci. World J.* **2011**, *11*, 2602–2612.

51. Guo, L.; Zhong, M.B.; Zhang, L.; Zhang, B.; Cai, D. Sex differences in Alzheimer’s disease: Insights from the multiomics landscape. *Biol. Psychiatry* **2021**, doi:10.1016/j.biopsych.2021.02.968.

52. Yang, Y.; Shepherd, C.; Halliday, G. Aneuploidy in Lewy body diseases. *Neurobiol. Aging* **2015**, *36*, 1253–1260.
53. Cano, J.; Granic, A.; Rademakers, R.; Dickson, D.W.; Coughlan, C.M.; Chial, H.J.; Potter, H. Mitotic defects lead to neuronal aneuploidy and apoptosis in frontotemporal lobar degeneration caused by MAPT mutations. *Mol. Biol. Cell* **2018**, *29*, 575–586.

54. Rossi, G.; Conconi, D.; Panzeri, E.; Redaelli, S.; Piccoli, E.; Paoletta, L.; Dalprà, L.; Tagliavini, F. Mutations in MAPT gene cause chromosome instability and introduce copy number variations widely in the genome. *J. Alzheimers Dis.* **2013**, *33*, 969–982.

55. Gentile, G.; La Cognata, V.; Cavallaro, S. The contribution of CNVs to the most common aging-related neurodegenerative diseases. *Aging Clin. Exp. Res.* **2020**, doi:10.1007/s40520-020-01485-4.

56. Sferra, A.; Nicita, F.; Bertini, E. Microtubule dysfunction: A common feature of neurodegenerative diseases. *Int. J. Mol. Sci.* **2020**, *21*, 7354.

57. Yurov, Y.B.; Vorsanova, S.G.; Iourov, I.Y. Chromosome instability in the neurodegenerating brain. *Front. Genet.* **2019**, *10*, 892.

58. Baker, D.J.; Petersen, R.C. Cellular senescence in brain aging and neurodegenerative diseases: Evidence and perspectives. *J. Clin. Investigig.* **2018**, *128*, 1208–1216.

59. Martínez-Cué, C.; Rueda, N. Cellular senescence in neurodegenerative diseases. *Front. Cell. Neurosci.* **2014**, *10*, 14.

60. Saez-Atienzar, S.; Masliah, E. Cellular senescence and Alzheimer disease: The egg and the chicken scenario. *Nat. Rev. Neurosci.* **2020**, *21*, 433–444.

61. van Deursen, J.M. The role of senescent cells in ageing. *Nature* **2014**, 509, 439–446.

62. Sikora, E.; Bielak-Zmijewska, A.; Dudkowska, M.; Krzystyniak, A.; Mosieniak, G.; Wiesierska, M.; Wlodarczyk, J. Cellular senescence in brain aging. *Front. Aging Neurosci.* **2021**, *13*, 646924.

63. Flanary, B.E.; Sammons, N.W.; Nguyen, C.; Walker, D.; Streit, W.J. Evidence that aging and amyloid promote microglial cell senescence. *Rejuvenation Res.* **2007**, *10*, 61–74.

64. Ogrodnik, M. Cellular aging beyond cellular senescence: Markers of senescence prior to cell cycle arrest in vitro and in vivo. *Aging Cell* **2021**, *20*, e13338.

65. Fricker, M.; Tolkovsky, A.M.; Borutaita, V.; Coleman, M.; Brown, G.C. Neuronal cell death. *Physiol. Rev.* **2018**, *98*, 813–880.

66. López-Otin, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. *Cell* **2013**, *153*, 1194–1217.

67. Barroso-Vilares, M.; Macedo, J.C.; Reis, M.; Warren, J.D.; Compton, D.; Logarinho, E. Small-molecule inhibition of aging-associated chromosomal instability delays cellular senescence. *EMBO Rep.* **2020**, *21*, e49248.

68. Vorsanova, S.G.; Yurov, Y.B.; Iourov, I.Y. Dynamic nature of somatic chromosomal mosaicism, genetic-environmental interactions and therapeutic opportunities in disease and aging. *Mol. Cytogenet.* **2020**, *13*, 16.

69. Faggioli, F.; Wang, T.; Vija, J.; Montagna, C. Chromosome-specific accumulation of aneuploidy in the aging mouse brain. *Hum. Mol. Genet.* **2012**, *21*, 5246–5253.

70. Frischer, H.G.; Morawska, M.; Brückner, M.K.; Mittag, A.; Tarnok, A.; Arendt, T. Changes in neuronal DNA content variation in the human brain during aging. *Aging Cell* **2012**, *11*, 628–633.

71. Andriani, G.A.; Vija, J.; Montagna, C. Mechanisms and consequences of aneuploidy and chromosome instability in the aging brain. *Mol. Ageing Dev.* **2017**, *161*, 19–36.

72. Macedo, J.C.; Vaz, S.; Logarinho, E. Mitotic dysfunction associated with aging hallmarks. *Adv. Exp. Med. Biol.* **2017**, *1002*, 153–188.

73. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Somatic cell genomics of brain disorders: A new opportunity to clarify genetic-environmental interactions. *Cytogenet. Genome Res.* **2013**, *139*, 181–188.

74. Barroso-Vilares, M.; Logarinho, E. Chromosomal instability and pro-inflammatory response in aging. *Mol. Ageing Dev.* **2019**, *182*, 111118.

75. Hägg, S.; Jylhävä, J. Sex differences in biological aging with a focus on human studies. *Elife* **2021**, *10*, e63425.

76. Thadathil, N.; Hori, R.; Xiao, J.; Khan, M.M. DNA double-strand breaks: A potential therapeutic target for neurodegenerative diseases. *Chromosome Res.* **2019**, *27*, 345–364.

77. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B.; Zelenova, M.A.; Kurinnaia, O.S.; Vasin, K.S.; Kutsev, S.I. The cytogenomic “theory of everything”: Chromohelkosis may underlie chromosomal instability and mosaicism in disease and aging. *Int. J. Mol. Sci.* **2020**, *21*, 8328.

78. Pathak, R.U.; Soujanya, M.; Mishra, R.K. Deterioration of nuclear morphology and architecture: A hallmark of senescence and aging. *Aging Res. Rev.* **2021**, *67*, 101264.

79. Petr, M.A.; Tulika, T.; Carmona-Marin, L.M.; Scheibye-Knudsen, M. Protecting the aging genome. *Trends Cell Biol.* **2020**, *30*, 117–132.

80. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Pathway-based classification of genetic diseases. *Mol. Cytogenet.* **2019**, *12*, 4.

81. Melo Pereira, S.; Ribeiro, R.; Logarinho, E. Approaches towards longevity: Reprogramming, senolysis, and improved mitotic competence as anti-aging therapies. *Int. J. Mol. Sci.* **2019**, *20*, 938.

82. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. The variome concept: Focus on CNVvariome. *Mol. Cytogenet.* **2019**, *12*, 52.

83. Heng, H.H. New data collection priority: Focusing on genome-based bioinformation. *Res. Results Biomed.* **2020**, *6*, 5–8.

84. Chronister, W.D.; Burbulis, I.E.; Wiernman, M.B.; Wolpert, M.J.; Haakenson, M.F.; Smith, A.C.B.; Kleinman, J.E.; Hyde, T.M.; Weinberger, D.R.; Bekiranov, S.; et al. Neurons with complex karyotypes are rare in aged human neocortex. *Cell Rep.* **2019**, *26*, 825–835.e7.

85. Iourov, I.Y.; Vorsanova, S.G.; Yurov, Y.B. Single cell genomics of the brain: Focus on neuronal diversity and neuropsychiatric diseases. *Curr. Genom.* **2012**, *13*, 477–488.

86. Medvedev, Z.A. An attempt at a rational classification of theories of ageing. *Biol. Rev. Camb. Philos. Soc.* **1990**, *65*, 375–398.